Second-Line Agents in the Treatment of Arthritis

Part 1 Evaluation and use of second-line agents: distinction between NSAIDs, corticosteroids and second-line agents, J.P. Famaey; variable disease and variable response to second-line agents, G. David Champion and Malcolm L. Handel; problems in the design and interpretation of trials of second-line agents, Ken J. Bulpitt and Harold E. Paulus; assessment procedures for monitoring second-line agents, Paul W. Thompson; predictors of risk from the use of second-line agents in rheumatoid arthritis, Alan J. Silman; decision making - the choice of second-line agents in the United States, Bonnie Hepburn; decision making - the choice of second-line agents in Europe and the United Kingdom, T. Pullar; decision making - the choice of second-line agents in Australia, P.M. Brooks et al; comments on decision making - the choice of second-line agents, Daniel E. Furst. Part 2 Second-line agents in the treatment of rheumatoid arthritis: gold therapy - a choice in the 1990s, H.A. Capell and H. Torley; penicillamine, J.K. van der Korst and A.O. Muijsers; purine analogs, Robert J.R. McKendry; antimalarials, R.I. Rynes; sulfonamides, Deborah E. Bax; methotrexate, D. Mathers and A.S. Russell; cyclosprin, W.B. Harrison; alkylating agents, P.J. Clements. Part 3 Second-line agents in the treatment of other arthritides: second-line agents in osteoarthritis, Peter Ghosh et al; treatment of seronegative polyarthritis, V. Neumann and V. Wright; second-line agents in systemic lupus erythematosus, Mary Betty Stevens and Carol M. Ziminski; second-line treatment of crystal-induced synovitis, J.T. Scott; second-line agents in the treatment of systemic vasculitis, A.S.M. Jawad and D.G.I. Scott. Part 4 Second-line agents in the future: combination chemotherapy for rheumatoid arthritis, P.T. Dawes and M.J. Davis; trace element supplements for inflammatory disease, M.W. Whitehouse; new immunosuppressive agents, immune modulators and other drugs, Alan J. Lewis and Richard P. Carlson.